Arcas News
Atlanta, GA, United States - June 30, 2010
MDOUTLOOK®, the oncology intelligence initiative powered by The Arcas Group, today announced results from its 3rd Annual Quick Poll research launched following this month’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Within one week, 281 cancer treaters from 22 countries responded, making it the first market feedback available post-ASCO. The research yielded the following highlights for these therapeutic segments:
Maintenance Therapy in Hematologic Malignancies:
• Rituximab: Nearly all physicians already use as maintenance therapy in some patients with Follicular Lymphoma. Increase in usage after ASCO driven by physicians using rituximab maintenance in a higher proportion of their patients.
• Lenalidomide: ~75% of physicians are already using some lenalidomide maintenance therapy for Multiple Myeloma, however in a minority of patients. Increase in usage after ASCO driven by more physicians using it in more patients.
• ~3/4 of Physicians found the new information on maintenance therapy in Follicular Lymphoma and Multiple Myeloma of significant value and usefulness to their clinical practice.
Novel Immunotherapies for the Treatment of Cancers:
• Immunotherapy is used in ~15% of oncology treatment decisions, irrespective of line of treatment.
• Ipilumimab: Physician response to new data presented predicts strong market adoption in melanoma and rapid integration into practice (pending FDA approval).
• High-dose aldesleukin (HD-IL-2): Physicians positively view new information presented in renal cell carcinoma (SELECT trial).
• Sipuleucel-T: Physician response predicts moderate market adoption in prostate cancer of this recently FDA-approved product.
Current and Future Use of Oncology Biomarkers:
• Current use of biomarkers to guide diagnosis and treatment decision is heavily weighted towards breast and colorectal cancer (>80% patients).
• Biomarkers are also used in up to 50% of patients with lung cancer, prostate and ovarian cancers; far less in other cancers.
• Oncologists strongly value both FDA indications and inclusion in National Guidelines for their adoption of the biomarker in clinical practice.
• Physician usage of biomarkers is influenced by its patient selection benefits and as well as incremental diagnostic costs.
Developments in Oncology Practice Management:
• Overall survival is considered the most important clinical trial endpoint by oncologists for their clinical decision-making.
• About 1/3 of all respondents attended ASCO, with no country differences. This ratio was consistent in all 2010 MDOUTLOOK Quick Polls and as well as previous years.
Members of the MDOUTLOOK Strategy Council reflected that these results “validate the expected change in physician decision-making” and that “it will be interesting to follow-up on a regular basis to track these changes.”
Jan Heybroek, President of The Arcas Group, LLC, which powers MDOUTLOOK commented: “These Quick Polls perfectly demonstrate the ability of MDOUTLOOK to quickly and in a targeted manner capture the views of validated cancer physicians around the world, and turn this into actionable intelligence.”
The 3rd Annual Quick Polls from ASCO 2010 were developed in collaboration with Arcas’ media partner, Oncology Business Review. More information can be found here.
Full copies of the 3rd Annual MDOUTLOOK Quick Polls from ASCO are available upon request.
About MDOUTLOOK®
MDOUTLOOK has been developed with a singular focus: improved understanding of complex diseases leading to better patient care. Over 45,000 medical oncology professionals have opted into a network of their peers through the MDOUTLOOK Internet-based system to share information such as preferred treatment regimens for complex diseases and de-identified patient logs, as well as the factors that play a part in their clinical decision-making.
Physician members of MDOUTLOOK benefit by having access to data on how other clinicians in practice treat difficult cases and how they are adapting to changes in the industry, everything from the introduction of new drugs or treatment modalities, to the rising costs of certain treatments. For many physicians, MDOUTLOOK also serves as a patient registry.
MDOUTLOOK is guided a Strategy Council of globally recognized experts: Chandra Belani, MD; Alexander Eggermont, MD, PhD; Keith Flaherty, MD; William Gradishar, MD; Axel Hauschild, MD; Peter Heald, MD; John Kirkwood, MD; Sagar Lonial, MD; Lauren Pinter-Brown, MD; Giorgio Scagliotti, MD, PhD; Joyce O’Shaughnessy, MD, and Nicholas Thatcher, MD.
MDOUTLOOK delivers life-sciences clients real-time ThoughtLeader and clinician-driven analysis, intelligence and insight into oncology clinical practice (www.thearcasgroup.com/mdoutlook).
About The Arcas Group
The Arcas Group is a strategic life sciences marketing organization with a singular focus: Supporting the commercial success of our clients in the continuum of life sciences marketing – from marketing intelligence to strategy development and implementation – through enhanced connectivity with ThoughtLeaders and Clinicians. MDOUTLOOK is a key offering that is highly valued by its rapidly expanding base of clients.
For a copy of the original press release, please click here.
July 9th, 2010
Today, Oncology Business Review (OBR) published a great article based on the results from the 3rd Annual MDoutlook Quick Poll following ASCO 2010. You can read the full article on OBR’s website (article). Many thanks to our friends at media partner OBR for developing and releasing this article so quickly after we published the analyzed results.
If you would like to receive a full copy of the MDoutlook Quick Poll analysis or learn more about the value and insight MDoutlook can deliver, please contact us using this form.
June 30th, 2010
We are pleased to report continued growth on a number of fronts!
Our team will welcome two valuable additions in July: Luan Dao, PhD will join the Medical Team as Global Medical Analyst and Jessica Mastrodomenico, MPH will strengthen our Operational Group as Manager, Client Projects. Luan most recently served as a post-doctoral fellow at Emory University with a focus on influenza and HPV. Jessica joins us from the CDC Foundation where she worked while completing her Master of Public Health with a concentration on prevention sciences.
We have also signed up three new clients for MDoutlook, our oncology intelligence platform. The clients specifically focus on prostate cancer, renal cell carcinoma and melanoma. Additionally, Arcas has welcomed new clients to its Outcome Optimizer offering in the area of oncology diagnostics and breast cancer. And our Business Optimizer offering has recently signed up tow consultancy projects focused on physician recruiting and oncology marketing.
Please contact us here for more information and if you are interested in joining a rapidly growing organization, either as client or associate.
June 30th, 2010
To support our continued growth and the successful delivery of client projects, we are looking for a Medical Analyst to join our team. Primary role will be to provide in-depth analysis and understanding of current physician treatment decisions and their underlying rationale(s) within specific therapy areas in the field of oncology. A full description of the position can be accessed here.
If you are interested in applying, please email us your resume and overview of qualifications at hr@thearcasgroup.com. We look forward to hearing from qualified candidates only.
May 14th, 2010
We are very pleased to announce that Annemiek Kuijsten has recently strengthened the Arcas leadership team as Director, Strategic Development Europe. She offers our clients and our team an impressive experience in hematology and oncology commercialization and education.
Prior to establishing the European branch of The Arcas Group, Annemiek worked for the European Hematology Association (EHA) where she managed both EHA’s relationships with Corporate Supporters and the annual congress. Under her leadership, EHA significantly expanded its base of corporate supporters and congress attendance grew year-over-year.
“I am thrilled to welcome Annemiek to our team. On several points in my career, Annemiek and I have collaborated successfully. She brings tremendous drive, energy, insight and understanding to our team and our clients,” says Jan Heybroek, President of The Arcas Group, LLC.
Annemiek may be reached directly at akuijsten@thearcasgroup.com.
April 29th, 2010
Atlanta - April 29, 2010
We are excited to announce our expansion! We have moved our main office to a new, larger location in Atlanta, GA. And, to better serve our clients, we have opened both a Philadelphia and European office. These milestones have been possible because of you, and we truly appreciate the relationship with our clients.
In only a few years, The Arcas Group has become a leading provider of marketing services focused on driving your commercial success through enhanced connectivity with ThoughtLeaders and Clinicians.
▪ MDOUTLOOK® | Oncology Intelligence and ThoughtLeader Insight
Unique web-based, disease intelligence platform synthesizing a comprehensive view of clinical decision patterns and treatment choices with clinician, ThoughtLeader and Institution profiling.
▪ Business Optimizer™ | Growth Consultancy
Integrated strategic consulting and marketing services to drive your commercial growth.
▪ Outcome Optimizer™ | Medical Strategy Implementation
Delivering novel concepts to implement your commercialization strategy with unrivalled access to clinicians and ThoughtLeaders.
Please explore this website for our latest market insights and services or contact us here.
April 29th, 2010
The article “The Big Reset” reviews the first decade of the millennium, and discusses trends and forecasts for 2010. It has been published in the January edition of Pharmaceutical Executive. Arcas President Jan Heybroek is quoted in the piece on pharma licensing trends as: “Yet the jump in the number of givebacks in 2009 may signal a resurgeance in acquisitions in 2010. You have to very actively manage licensing relationships, and there’s plenty of evidence that the divorce rate is as high as it is for people.” You can read a full copy of the article here: The Big Reset - PharmExec Jan 2010.
For more information on Arcas and MDoutlook, our unique and innovative oncology intelligence resource, please contact us at 1.866.3outlook | +1.404.496.4136 | email.
February 17th, 2010
Earlier this month, MDoutlook® - our unique and innovative oncology intelligence resource - reached another milestone: profiles of more than 45,000 oncology treaters worldwide now are available.
MDoutlook provides unprecedented insight into several key areas of the oncology landscape in a disease-targeted manner. These areas include:
- ThoughtLeader, practicing clinician, and institutional profiling combining physician-self and Arcas-team validated and updated information with real-time data feeds from reputable external sources;
- Real-time treatment logs of patients per oncology disease target;
- Individual and aggregate physician treatment profiling, inclusive of patient flow and volume;
- And, through the MyActivities Module of MDoutlook, an unmatched resource and platform for the daily collection, analysis and reporting of sales and marketing interactions, company activities and market intelligence, at the individual ThoughtLeader and practicing clinician levels.
MDoutlook uncovers not only the therapeutic choices oncologists make (quantitative), and the considerations, rationale, and ThoughtLeaders influencing their decisions (qualitative), in one easily accessible, focused resource. This insight is captured through targeted surveys to physicians treating the target disease, dedicated treater panels/treatment logs, and corresponding analyses and reports. And importantly, this insight is guided and interpreted through direct and exclusive consultation with top peer-identified ThoughtLeaders in each of the target disease areas.
The MDoutlook Intelligence Platform features in-depth and easily accessed information for your entire organization; real-time updating of streaming data; on-demand information sorting, prioritization analysis, and reporting; interactive links between networks of clinicians, ThoughtLeaders, and Institutions; and sophisticated information searching.
Interested? Please contact us at +1.866.3outlook | 1.404.496.4136 | email for more information and to schedule a demo.
February 17th, 2010
We are proud to announce our support and affiliation with the 2nd Oncology USA Summit, to be held Mar 23-24 in Boston, MA. This exciting, first-tier event will offer our clients and other marketing executives new perspectives on oncology commercialization, and relevant case studies. As a client of Arcas, we are able to offer you an exclusive $300 discount on your conference registration - for more details and registration see below.
How do you engage all stakeholders in a challenging oncology market place? With 6 VP speaker insights and the top oncology companies represented, we will demonstrate how to articulate your value proposition to a wider audience.
This is your chance to be part of an interactive forum to ultimately take away knowledge that enables you to take your oncology commercialization strategy to the next level. This information-driven gathering will bring together senior level executives in the industry to network, as well as refreshing and refocusing your knowledge.
Event title: 2nd Annual Oncology USA
Dates: March 23-24 2010
Location: Boston Park Plaza, Boston, USA
Contact details: Claire Poole - cpoole@eyeforpharma.com
www.eyeforpharma.com/oncologyusa
To benefit from a special discount of $300 as valued Arcas client, please click on this registration link and quote ‘Arcas‘.
Looking forward to seeing you in Boston!
January 6th, 2010
In working so closely with our clients and over-delivering on our promises, client focus and project delivery is constantly and squarely front-of-brain. Our projects tend to be long(er) commitments in which our relationships develop as we look for more and better ways to support our clients’ success. It is a matter of great professional pride when we receive - unsolicited - accolades for our work.
Here is a recent selection:
- “I just want to thank you for the time we have been working together. I think it has been a great experience. Seldom do I come across a team so professional as you are; intelligent, knowledgeable, produce good things and on time. Very impressive.”
Executive, New Media Company - Boston, MA
- “You are true oncology experts. I trust your guidance and recommendations implicitly. I have been in oncology marketing for almost two decades and your network of thoughtleaders is unsurpassed.”
Director, Oncology Marketing - San Diego, CA
- “MDoutlook is delivering exactly the oncology intelligence I was looking for. I’m slightly overwhelmed by the amount of information you have been able to uncover, analyze and deliver in less than 30 days.”
Director, Marketing - Princeton, NJ
- “Your team is awesome. The quality of the deliverables and the ease of collaboration is much better what the two previous companies were able to provide me. I love it!”
Renowned Breast Cancer Expert - Miami, FL
Contact us at info@thearcasgroup.com, +1.404.496.4136 for more information, client references and to discuss how we can support your commercial growth.
December 7th, 2009
Previous Posts
